Our Readers over the years (since 2012!) have been tracking the rise–and fall–of IBM Watson Health. Now sold to Francisco Health [TTA 22 Jan], multiple companies have taken up chunks of their all-too-unwieldy mission, from oncology analytics and diagnostics to clinical decision making, and managing (and, in one case, reversing) chronic conditions. MM+M (Medical Marketing and Media) profiled ten companies–5 in diagnosis and 5 in treatment–in two articles. The first five are closer to the original Watson than the second group.
- Heartflow–diagnosis of coronary artery disease
- PathAI–machine learning for pathology in bladder and skin cancer detection
- Paige.AI–AI and pathology in prostate cancer detection
- Exo–medical imaging
- Proscia–dermatology diagnosis for melanoma
- Atropos Health–converting EHR information for clinical decision making and follow up
- Virta Health–prescribing food plans to people to reverse Type 2 diabetes, management via AI to doctors
- Sword Health–virtual care for patients with musculoskeletal (MSK) pain, managed by pairing them with digital therapy, monitoring by motion sensors
- Omada Health–personal interventions in chronic conditions
- Twin Health–sensor based monitoring and machine learning to reverse chronic diseases
Most Recent Comments